Clinical trial · Observational
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women
NCT01077817CI-TRIAL-00056315completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alendronate | Drug | — | UNRESOLVED |
| Etidronate | Drug | — | UNRESOLVED |
| Ibandronate | Drug | Ibandronic Acid | ALIAS |
| Raloxifene | Drug | — | UNRESOLVED |
| Risedronate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- label
- Esophageal Cancer Cases
- description
- Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
- interventionNames
- Drug: Alendronate
- Drug: Etidronate
- Drug: Ibandronate
- Drug: Risedronate
- Drug: Raloxifene
- label
- Comparison Sample (Case-Cohort)
- description
- Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
- interventionNames
- Drug: Alendronate
- Drug: Etidronate
- Drug: Ibandronate
- Drug: Risedronate
- Drug: Raloxifene
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Cases: * Women in the database aged 55 or older between 1996 and 2008 with diagnosis of esophageal cancer * Comparator Controls: * Each case was matched to all women in the random subcohort of 25,000 who had the same year of birth as the case and were in the database at the time of diagnosis. Exclusion Criteria: * Women with diagnosis of any other cancer or Paget's Disease or who have received oral or intravenous steroids before the index date
References
Publications (0)
Data not yet available
No reference posted for this study.